Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
4.570
+0.215 (4.94%)
At close: Aug 13, 2025, 4:00 PM
4.610
+0.040 (0.88%)
After-hours: Aug 13, 2025, 5:52 PM EDT
Vir Biotechnology Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Vir Biotechnology stock ranges from a low of $12 to a high of $110. The average analyst price target of $30.25 forecasts a 561.93% increase in the stock price over the next year.
Price Target: $30.25 (+561.93%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 11, 2025.
Analyst Ratings
The average analyst rating for Vir Biotechnology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Initiates $12 | Buy | Initiates | $12 | +162.58% | Jul 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +206.35% | May 22, 2025 |
| Needham | Needham | Strong Buy Maintains $19 → $14 | Strong Buy | Maintains | $19 → $14 | +206.35% | May 12, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $21 | Strong Buy | Maintains | $28 → $21 | +359.52% | Apr 17, 2025 |
| Barclays | Barclays | Buy Maintains $26 → $31 | Buy | Maintains | $26 → $31 | +578.34% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
17.11M
from 74.21M
Decreased by -76.94%
Revenue Next Year
17.21M
from 17.11M
Increased by 0.56%
EPS This Year
-3.13
from -3.83
EPS Next Year
-3.04
from -3.13
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.4M | 55.2M | 49.5M | ||
| Avg | 17.1M | 17.2M | 25.1M | ||
| Low | 2.9M | 2.9M | 4.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.8% | 222.5% | 187.7% | ||
| Avg | -76.9% | 0.6% | 45.9% | ||
| Low | -96.0% | -82.8% | -71.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.60 | -2.34 | -1.68 | ||
| Avg | -3.13 | -3.04 | -2.77 | ||
| Low | -3.68 | -4.15 | -3.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.